(HealthDay)—There is an unfavorable pharmacological drug interaction between the non-narcotic analgesic dipyrone and aspirin in patients with coronary artery disease (CAD), according to research published online Aug. 14 in the Journal of the American College of Cardiology.
Amin Polzin, M.D., from the Heinrich Heine University Medical Center in Düsseldorf, Germany, and colleagues studied three subgroups of CAD patients with optimal medical therapy according to current guidelines. Group A included 10 CAD patients in whom aspirin had been withdrawn because of scheduled cardiac surgery; group B included 20 CAD patients taking aspirin; and group C included 36 patients with a co-medication of aspirin/dipyrone. Seventy-five percent of patients in groups B and C were on dual antiplatelet therapy with clopidogrel. Platelet function was measured by arachidonic acid-induced light-transmission aggregometry and thromboxane B2-formation by immunoassay.
The researchers found that patients not taking aspirin had effective platelet aggregation. In group B patients, thromboxane formation was nearly completely inhibited. Patients in group C restituted arachidonic acid-induced thromboxane formation to levels sufficient for complete restoration of platelet aggregation; an impaired aspirin effect was seen in half of group C's co-medicated patients.
"Dipyrone co-medication in CAD patients can completely blunt the antiplatelet effects of aspirin," the authors write.
Explore further: OK to continue aspirin therapy up to pancreatic surgery
More information: Full Text (subscription or payment may be required)
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Aspirin enhances platelet isoprostanes in type 2 diabetes
Mar 23, 2012
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published ...
OK to continue aspirin therapy up to pancreatic surgery
Aug 01, 2013
(HealthDay)—Patients on aspirin therapy do not have higher rates of perioperative bleeding, transfusion, or major procedure-related complications following elective pancreatic surgery, according to research ...
Global platelet reactivity and high risk ACS patients
Aug 28, 2012
Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.
New class of platelet blockers proves effective in phase III trial
Mar 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...
1-year results of ADAPT-DES trial published in The Lancet
Jul 26, 2013
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less ...
Recommended for you
Flu vaccination protects patients at risk for acute MI
20 minutes ago
(HealthDay)—Recent influenza does not predict acute myocardial infarction (AMI), but vaccination offers a significant protective benefit for the prevention of AMI, according to research published online ...
Risk factor reduction after heart attack—age, race, and gender matter
2 hours ago
Risk factor modification efforts could help reduce the chance of another heart attack and death among the more than 15 million Americans with coronary heart disease. Yet some patients—especially women and ...
Flu jab may halve heart attack risk in middle aged with narrowed arteries
20 hours ago
The flu jab seems to almost halve the risk of heart attacks in middle aged people with narrowed arteries, finds research published in the journal Heart.
What is your heart attack risk?
23 hours ago
Researchers in India have carried out a data mining exercise to determine which are the most important risk factors in increasing the chances of an individual suffering a heart attack. Writing in the International Journal of ...
'Virtual heart' precision-guides defibrillator placement in children with heart disease
Aug 21, 2013
The small size and abnormal anatomy of children born with heart defects often force doctors to place lifesaving defibrillators entirely outside the heart, rather than partly inside—a less-than-ideal solution to dangerous ...
Use of tPA for ischemic stroke nearly doubled from 2003 to 2011
Aug 21, 2013
Use of the "clot-busting" drug tissue plasminogen activator (tPA) to treat patients with strokes caused by a blockage of blood flow nearly doubled between 2003 and 2011. In their paper receiving online release in the journal ...
User comments
© Medical Xpress 2011-2013, Phys.org network
(HealthDay)—There is an unfavorable pharmacological drug interaction between the non-narcotic analgesic dipyrone and aspirin in patients with coronary artery disease (CAD), according to research published online Aug. 14 in the Journal of the American College of Cardiology.
Amin Polzin, M.D., from the Heinrich Heine University Medical Center in Düsseldorf, Germany, and colleagues studied three subgroups of CAD patients with optimal medical therapy according to current guidelines. Group A included 10 CAD patients in whom aspirin had been withdrawn because of scheduled cardiac surgery; group B included 20 CAD patients taking aspirin; and group C included 36 patients with a co-medication of aspirin/dipyrone. Seventy-five percent of patients in groups B and C were on dual antiplatelet therapy with clopidogrel. Platelet function was measured by arachidonic acid-induced light-transmission aggregometry and thromboxane B2-formation by immunoassay.
The researchers found that patients not taking aspirin had effective platelet aggregation. In group B patients, thromboxane formation was nearly completely inhibited. Patients in group C restituted arachidonic acid-induced thromboxane formation to levels sufficient for complete restoration of platelet aggregation; an impaired aspirin effect was seen in half of group C's co-medicated patients.
"Dipyrone co-medication in CAD patients can completely blunt the antiplatelet effects of aspirin," the authors write.
Explore further: OK to continue aspirin therapy up to pancreatic surgery
More information: Full Text (subscription or payment may be required)
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Aspirin enhances platelet isoprostanes in type 2 diabetes
Mar 23, 2012
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published ...
OK to continue aspirin therapy up to pancreatic surgery
Aug 01, 2013
(HealthDay)—Patients on aspirin therapy do not have higher rates of perioperative bleeding, transfusion, or major procedure-related complications following elective pancreatic surgery, according to research ...
Global platelet reactivity and high risk ACS patients
Aug 28, 2012
Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.
New class of platelet blockers proves effective in phase III trial
Mar 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...
1-year results of ADAPT-DES trial published in The Lancet
Jul 26, 2013
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less ...
Recommended for you
Flu vaccination protects patients at risk for acute MI
20 minutes ago
(HealthDay)—Recent influenza does not predict acute myocardial infarction (AMI), but vaccination offers a significant protective benefit for the prevention of AMI, according to research published online ...
Risk factor reduction after heart attack—age, race, and gender matter
2 hours ago
Risk factor modification efforts could help reduce the chance of another heart attack and death among the more than 15 million Americans with coronary heart disease. Yet some patients—especially women and ...
Flu jab may halve heart attack risk in middle aged with narrowed arteries
20 hours ago
The flu jab seems to almost halve the risk of heart attacks in middle aged people with narrowed arteries, finds research published in the journal Heart.
What is your heart attack risk?
23 hours ago
Researchers in India have carried out a data mining exercise to determine which are the most important risk factors in increasing the chances of an individual suffering a heart attack. Writing in the International Journal of ...
'Virtual heart' precision-guides defibrillator placement in children with heart disease
Aug 21, 2013
The small size and abnormal anatomy of children born with heart defects often force doctors to place lifesaving defibrillators entirely outside the heart, rather than partly inside—a less-than-ideal solution to dangerous ...
Use of tPA for ischemic stroke nearly doubled from 2003 to 2011
Aug 21, 2013
Use of the "clot-busting" drug tissue plasminogen activator (tPA) to treat patients with strokes caused by a blockage of blood flow nearly doubled between 2003 and 2011. In their paper receiving online release in the journal ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment